Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response DOI Creative Commons
Faruk Özalp, Kutsal Yörükoğlu, Eda Yildirim

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 29, 2024

Renal cell carcinoma (RCC) is characterised by its immunogenic and proangiogenic nature resistance to conventional therapies. The advent of immune checkpoint inhibitors (ICIs) tyrosine kinase (TKIs) has significantly improved patient survival, but these treatments remains a challenge. B7-H3, potential checkpoint, been implicated in modulating the tumour microenvironment escape mechanisms RCC. Immunohistochemical analysis B7-H3 expression was performed 84 metastatic RCC patients. Tissue microarrays separate sections formalin-fixed paraffin-embedded tissue were used for immunohistochemical staining. Membranous staining tumor cells scored statistical analyses assess correlation between treatment outcome. absent 31% patients, while 33.3% had score 1+, 2+, 4.8% 3+. High correlated with poorer OS (20 months vs. 45 months, p = 0.012). In patients receiving nivolumab, those high shorter PFS (2 8 0.037) (17 51 0.01). only factor affecting multivariate analysis. associated survival outcomes reduced response nivolumab may serve as predictive biomarker immunotherapy response. Future studies should explore targeting combination existing therapies enhance efficacy.

Language: Английский

Deep Learning Algorithm‑Based MRI Radiomics and Pathomics for Predicting Microsatellite Instability Status in Rectal Cancer: A Multicenter Study DOI

Xiuzhen Yao,

Shuitang Deng,

Xiaoyu Han

et al.

Academic Radiology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

4
The Role of the Dysregulation of circRNAs Expression in Glioblastoma Multiforme DOI
Yafei Wang, Ying Yu, Jiahua Yu

et al.

Journal of Molecular Neuroscience, Journal Year: 2025, Volume and Issue: 75(1)

Published: Jan. 22, 2025

Language: Английский

Citations

0
Effectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case DOI Open Access
А. S. Polyakova, Sokolov Ea, Pushkar' DIu

et al.

Cancer Urology, Journal Year: 2025, Volume and Issue: 20(4), P. 104 - 111

Published: Feb. 28, 2025

Sarcomatoid variant of urothelial carcinoma is a rare histological subtype: it diagnosed in 0.1–0.3 % all neoplasms the bladder. The standard 1 st line therapy for types advanced chemotherapy which does not necessarily allow to achieve best or complete responses, especially presence sarcomatoid differentiation. High programmed cell death-ligand (PD-L1) expression this morphological subtype allows assume better results immunotherapy compared chemotherapy. However, large number observations necessary confirm hypothesis and suggest pembrolizumab as 1st metastatic with

Language: Английский

Citations

0
Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies DOI Open Access

Suman Giri,

Gopal Lamichhane, Jitendra Pandey

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2923 - 2923

Published: March 24, 2025

Understanding the modulation of specific immune cells within tumor microenvironment (TME) offers new hope in cancer treatments, especially immunotherapies. In recent years, and resistance to immunotherapy have become critical challenges treatments. However, novel strategies for emerged as promising approaches oncology due vital roles immunomodulators regulating progression metastasis modulating immunological responses standard care With progress immuno-oncology, a growing number mechanisms are being uncovered, offering potential enhanced clinical near future. Thus, gaining comprehensive understanding broader context is essential. Herein, we particularly summarize paradoxical role tumor-related cells, focusing on how targeted their actions modulated by immunotherapies overcome immunotherapeutic cells. We also highlight molecular employed tumors evade long-term effects agents, rendering them ineffective.

Language: Английский

Citations

0
Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis DOI Creative Commons
Jun Xie, Qing Mao, Junhao Chen

et al.

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 9, 2025

There is still controversy regarding the safety and efficacy of atezolizumab for treatment urothelial carcinoma (UC). This research aimed to extensively investigate effectiveness as a therapy UC. A thorough literature review was conducted using databases including PubMed, Embase, Cochrane Library, Web Science. The search included studies published from inception each database until May 24, 2024. primary outcomes, progression-free survival (PFS) overall (OS), were calculated hazard ratios (HRs) their corresponding 95% confidence intervals (CIs). Ten randomized controlled trials (RCTs) totaling 4,148 participants in our analysis. Compared UC patients who received placebo, either alone or combination with chemotherapy medications, aggregated data showed that had significantly longer OS(HR = 0.88, CI [0.83, 0.94], p < 0.0001). Three RCTs also provided on PFS, showing atezolizumab, addition instead chemotherapy, PFS than those placebo without (HR 0.85, [0.76, 0.95], 0.004). Atezolizumab has demonstrated significant improvements OS among UC, offering crucial insights decision-making immunotherapy. https://www.crd.york.ac.uk/PROSPERO/#recordDetails , identifier [CRD42024556757].

Language: Английский

Citations

0
Comprehensive bioinformatics and immunohistochemical analyses identify phosphoinositide metabolism and PNPLA7 as potential biomarkers in urological cancers DOI Creative Commons
Yinhao Chen, Mingde Gao, Peng Chen

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 12, 2025

Phosphoinositides (PI) and their metabolic enzymes are known to be involved in cellular processes associated with the hallmarks of cancer. The impact PI metabolism-related components on urinary tract (or urological) cancers, however, remains unexplored. Considering this, herein, we performed a comprehensive bioinformatic analysis clear cell renal carcinoma, bladder cancer, adenocarcinoma prostate using public databases investigate relative contribution metabolism these clinical phenotypes. Primarily, computed phosphoinositide scores assess biological further enriched by predicting drug sensitivity, immune profiling, risk stratification. Besides, utilized single-cell RNA sequencing datasets identify intercellular communication networks cancer subtypes. Of interest, our identified PNPLA7 gene as potential biomarker urological which validated immunohistochemical evaluation samples. In conclusion, study reveals that is critical prognostic for cancers may guide therapies, including immunosuppressants. Therefore, could serve target requires attention.

Language: Английский

Citations

0
Natural Compounds in Cancer Therapy: Revealing the Role of Flavonoids in Renal Cell Carcinoma Treatment DOI Creative Commons
Zixuan Chen, Min Liu

Biomolecules, Journal Year: 2025, Volume and Issue: 15(5), P. 620 - 620

Published: April 25, 2025

Renal cell carcinoma (RCC) is the most lethal malignancy of urinary system, with limited treatment options due to drug resistance and adverse effects associated current therapies. This review aims systematically examine therapeutic potential flavonoids, which are natural polyphenolic compounds possessing anti-inflammatory, antioxidant, anticancer properties, in context RCC treatment. We summarize activities 26 classified into six subclasses, explore their mechanisms action, including inhibition tumor proliferation, migration, invasion, as well induction apoptosis, autophagy, ferroptosis. Particular attention paid modulation key signaling pathways such JAK/STAT3, PI3K/Akt/mTOR, miRNA-related axes, miR-21/YAP1 miR-324-3p/GPX4, providing a molecular basis for anti-RCC activity. also address several pharmacological challenges that limit clinical application poor bioavailability, metabolic instability, toxicity. Emerging solutions novel flavonoid derivatives, advanced delivery systems, rational combination therapy strategies discussed. Current evidence, phase II trial flavopiridol RCC, highlights but need further validation. In conclusion, flavonoids offer promising approach improving Future research should focus on optimizing efficacy ensuring safe translation, goal achieving personalized minimally invasive cancer

Language: Английский

Citations

0
Revealing the Mechanism of Esculin in Treating Renal Cell Carcinoma Based on Network Pharmacology and Experimental Validation DOI Creative Commons
Zixuan Chen,

Cunzhou Wang,

Yuesong Cai

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(8), P. 1043 - 1043

Published: Aug. 22, 2024

Purpose: This study aims to explore the potential mechanisms of esculin in treatment renal cell carcinoma (RCC). Methods: We employed network pharmacology predict and targets RCC. Molecular docking techniques were then validate predicted targets. Additionally, a series vitro experiments conducted verify anticancer effects on RCC cells, including CCK-8 assay, EdU wound healing apoptosis Western blot. Results: Network molecular results identified GAPDH, TNF, GSK3B, CCND1, MCL1, IL2, CDK2 as core GO KEGG analyses suggested that may influence apoptotic processes target PI3K/Akt pathway Furthermore, assay demonstrated inhibited viability. Microscopic observations revealed following treatment, there was an increase crumpling, reduction density, accumulation floating dead cells. with increasing concentrations, proportion EdU-positive cells decreased, closure ratio PI-positive increased, expression levels BAX cleaved-caspase-3 proteins level Bcl2 protein decreased. These findings inhibits proliferation migration while promoting apoptosis. Moreover, found GAPDH inhibit pathway. Conclusions: is first elucidate therapeutic The provide evidence supporting clinical application introduce promising new candidate for treatment.

Language: Английский

Citations

1
Stanniocalcin-1 in tumor immunity: acts via macrophages DOI Creative Commons

Lele Wang,

Jianjun Wang,

Weijie Qiang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 25, 2024

Tumor immune escape has become a research hotspot in the field of cancer immunotherapy. Tumor-associated macrophages (TAMs) are key component tumor microenvironment, which play pivotal role by regulating immunity checkpoints, inhibiting activity T lymphocytes and natural killer (NK) cells, modulating proportion different cells. Stanniocalcin-1(STC1)is ubiquitously expressed human body, is proven to involve with progression clinical prognosis. Recently, STC1 implicated microenvironment as phagocytosis checkpoint, well regulates via macrophages. In review, we discussed TAMs their crosstalk, hoping provide references for

Language: Английский

Citations

1
Bacillus Calmette-Guérin (BCG)-Induced Pneumonitis: A Case Report DOI Open Access

Ahmed Farrag,

Jhiamluka Solano,

Vijaykumar Singh

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 16, 2024

Bladder cancer is the second most common genitourinary (GU) malignancy worldwide. Treatment involves early cystectomy and intravesical Bacillus Calmette-Guérin (BCG), which effective for T1 high-grade tumors carcinoma in situ (CIS) but can cause significant side effects, including chemical bacterial cystitis, hematuria, incontinence, pneumonitis, malaise, fever, sepsis. We present case of a 47-year-old male with transitional cell (TCC, G3 pTa) treated transurethral resection bladder tumor (TURBT) who developed fever non-productive cough after BCG injections. Initially discharged, he returned worsened symptoms. His vital signs showed 38.2°C, heart rate 104 beats per minute (bpm), saturation 93% on room air. Blood tests indicated inflammation liver dysfunction. Imaging revealed lung micronodularity, further CT imaging bilateral miliary nodules indicative pneumonitis. MRI ruled out disseminated tuberculosis, identifying hepatic cyst. Cultures from blood, urine, sputum, broncho-alveolar lavage were negative, granulomatous was confirmed biopsy. The patient oral glucocorticoids anti-tuberculosis medications (rifampicin, isoniazid, ethambutol), clinical improvement shown. follow-up at respiratory clinic scheduled. severe therapy complication, necessitates diagnosis management to reduce morbidity mortality.

Language: Английский

Citations

0